The Weekly Dose: Rising Cyclosporiasis Cases, Psychedelic Therapy Safety Monitoring, and New FDA Approvals

This week’s episode of The Weekly Dose opens with a public health alert on cyclosporiasis, a parasitic gastrointestinal illness that has now surpassed 450 reported cases across 18 states, with Michigan accounting for more than 300 of them. While no single outbreak source has been identified, officials note the true case count is likely underreported. The segment highlights diagnostic challenges—routine stool cultures miss the parasite, requiring a specifically ordered modified acid-fast stain or polymerase chain reaction test—and reinforces the pharmacist’s role in counseling patients on persistent watery diarrhea, washing produce, and hand hygiene.

Next, the key opinion leader feature turns to psychedelic medicine. Aza Allsop, MD, PhD, of Yale and Howard universities, discusses what safety infrastructure might look like as psychedelic therapies move toward mainstream clinical use following a recent executive order aimed at accelerating their development. Allsop proposes a Risk Evaluation and Mitigation Strategy–style monitoring system to track treatment administration and prevent patients from receiving overlapping treatments across multiple centers, while emphasizing that institutional enthusiasm from schools such as Stanford University and Johns Hopkins University must be paired with an equitable, safety-first approach.

The policy roundup covers 4 major regulatory developments: the accelerated approval of atacicept-vymj (Trutakna) for IgA nephropathy, the first therapy targeting both BAFF and APRIL pathways; an expanded indication for exagamglogene autotemcel (Casgevy), now approved for children as young as 2 years with sickle cell disease or transfusion-dependent beta-thalassemia; the approval of Tregzi, the first cell therapy combining regulatory T cells, stem cells, and conventional T cells for transplant patients; and a significant expansion of the National Institute of Health’s All of Us Research Program, which now includes genomic and health data from more than 747,000 participants, over 86% of whom are from historically underrepresented groups.

Across every story, the episode underscores pharmacists’ expanding responsibilities in patient counseling, safety monitoring, and care coordination as new therapies and research tools reshape clinical practice.